• Christina Fragodimitri, Vasiliki Schiza, Anastasios Giakoumis, Kalliopi Drakaki, Anastasia Salichou, Fotis Karampatsos, Jacqueline Yousef, Markissia Karageorga, Vasili Berdoukas, and Athanasios Aessopos.
• Thalassemia Unit, "Aghia Sofia" Children's Hospital, Athens, Greece.
• Medicine (Baltimore). 2023 Oct 13; 102 (41): e35455e35455.

AbstractThis century has seen a revolution the management of beta-thalassemia major. Over a 12-year period to 2016, we aimed to analyze the benefits of such advances. In 209 patients, independent of the chelation regimen, ferritin, cardiac T2* and liver iron concentration changes were evaluated. We defined chelation success (ChS) as no iron load in the heart and acceptable levels in the liver. Over 3 early magnetic resonance imagings, the same parameters were assessed in 2 subgroups, the only 2 that had sufficient patients continuing on 1 regimen and for a significant period of time, 1 on deferrioxamine (low iron load patients n = 41, Group A) and 1 on deferoxamine-deferiprone (iron overloaded n = 60, Group B). Finally, 28 deaths and causes were compared to those of an earlier period. The 209 patients significantly optimized those indices, while the number of patients with chelation success, increased from 6% to 51% (P < .0001). In group A, ChS after about 8 years increased from 21 to 46% (P = .006), while in Group B, from 0% to 60% (P < .001) after about 7 years. Deaths over the 2 periods showed significant reduction. Combined clearance of cardiac and liver iron (ChS) is feasible and should become the new target for all patients. This requires, serial magnetic resonance imagings and often prolonged intensified chelation for patients.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

24 keywords...

hide…